Meeting
2023 ASCO Annual Meeting
Comparison of next-generation sequencing and flow cytometry in detecting minimal residual disease in adult acute lymphoid leukemia: Evaluating clinical outcomes in a single-center study.
Authors
Vinay Nittur
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA
Vinay Nittur , Karam Ashouri , Blake Adnani , Jennifer Hwang , Denaly Chen , Kimberly Schiff , Lakshmi Savitala-Damerla , Abdullah Ladha , Karrune Woan , Eric Leon Tam , Preet Chaudhary , George Yaghmour
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7033)
DOI
10.1200/JCO.2023.41.16_suppl.7033
Abstract #
7033
Poster Bd #
163
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Clinical applications of measurable residual disease monitoring by multi-parametric flow cytometry and next-generation sequencing in B-cell precursor acute lymphoblastic leukemia.
First Author: Gun-Dong Lee
Poster
2018 ASCO Annual Meeting
Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.
First Author: Elias Jabbour
First Author: Mark J. Levis
Poster
2023 ASCO Annual Meeting
Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring.
First Author: Joaquin Martinez-Lopez